Finding new treatments for diabetes--how many, how fast... how good?
Nathan
David M
DM
Diabetes Center, Massachusetts General Hospital, Boston, USA.
D058892:Adenosine Deaminase Inhibitors; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors; D017277:Drug Approval; D052216:Glucagon-Like Peptide 1 / Q000187:drug effects / Q000378:metabolism; D006023:Glycoproteins / Q000037:antagonists & inhibitors*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007004:Hypoglycemic Agents / Q000266:history / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000187:drug effects / Q000378:metabolism; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D058892:Adenosine Deaminase Inhibitors; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006023:Glycoproteins; D007004:Hypoglycemic Agents; D010446:Peptide Fragments; D011719:Pyrazines; D014230:Triazoles; D052216:Glucagon-Like Peptide 1; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4; C051322:glucagon-like peptide 1 (7-37); D000068900:Sitagliptin Phosphate